OBJECTIVES: To compare drug survival of different anti-TNF drugs (infliximab, INF, etanercept, ETA, and adalimumab, ADA) in rheumatoid arthritis (RA) and spondyloarthritis (SpA) by analysing data collected from an Italian multicenter observational cohort study. METHODS: All patients with RA or SpA registered in the MonitorNet database who started their first course of anti-TNF therapy were included. Overall drug survival was measured, along with specific reasons of discontinuation (inefficacy or adverse events). A first set of analyses using RA as reference category assessed the relationship between diagnosis and drug survival. A second set of analyses stratified by diagnosis (RA and SpA) used INF as reference drug. Adjustment for confounders was performed. The results are presented as adjusted hazard ratios (adjHR) and 95% confidence intervals (95%CI). RESULTS: 2640 RA patients and 1220 SpA patients with a median follow-up of 17 months (IQR 7.2-33.4) were included in the analyses. Patients with a diagnosis of SpA showed a lower risk of drug discontinuation with an adjHR (95%CI) of 0.81 (0.73, 0.90). In SpA, the subset of patients with ankylosing spondylitis (AS) showed the best survival on treatment. In RA, both ETA and ADA showed a significantly lower probability of withdrawal when compared to INF [adjHR (95%CI) 0.46 (0.38, 0.56) and 0.68 (0.57, 0.81), respectively]. Similar results were found in SpA. CONCLUSIONS: Drug survival for SpA is longer than that in RA mainly due to the AS subgroup. In both RA and SpA, ETA and ADA showed a better retention on treatment when compared to INF.

Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the Monitor Net database / Scirè, Ca; Caporali, R; Sarzi Puttini, P; Frediani, B; Di Franco, M; Tincani, A; Sinigaglia, L; Sfriso, P; Tirri, R; Bellis, E; Delsante, G; Porru, G; Salaffi, F; Giuggioli, D; Rossini, M; Todoerti, M; Bazzichi, L; Govoni, M; Gerli, R; Raschetti, R; Minisola, G; Montecucco, C; Todesco, S; Todesco, S; Raschetti, R; Naldi, L; Galeazzi, M; Sarzi Puttini, P; Fantini, F; Mathieu, A; Valesini, G; Ferri, Clodoveo; Bambara, Lm; Grassi, W; Trotta, F; Gerli, R; Adami, S; Lapadula, G; Pellerito, R; De Vita, S; Minisola, G; Foti, R; Paolazzi, G; Bagnato, G; Cutolo, M; Rocchetta, Pa; Ferraccioli, G; Canesi, Ba; Matucci Cerinic, M; Vittorio, M; Canzoni, M.. - In: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. - ISSN 0392-856X. - STAMPA. - 31:6(2013), pp. 857-863.

Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the Monitor Net database.

Giuggioli D;FERRI, Clodoveo;
2013

Abstract

OBJECTIVES: To compare drug survival of different anti-TNF drugs (infliximab, INF, etanercept, ETA, and adalimumab, ADA) in rheumatoid arthritis (RA) and spondyloarthritis (SpA) by analysing data collected from an Italian multicenter observational cohort study. METHODS: All patients with RA or SpA registered in the MonitorNet database who started their first course of anti-TNF therapy were included. Overall drug survival was measured, along with specific reasons of discontinuation (inefficacy or adverse events). A first set of analyses using RA as reference category assessed the relationship between diagnosis and drug survival. A second set of analyses stratified by diagnosis (RA and SpA) used INF as reference drug. Adjustment for confounders was performed. The results are presented as adjusted hazard ratios (adjHR) and 95% confidence intervals (95%CI). RESULTS: 2640 RA patients and 1220 SpA patients with a median follow-up of 17 months (IQR 7.2-33.4) were included in the analyses. Patients with a diagnosis of SpA showed a lower risk of drug discontinuation with an adjHR (95%CI) of 0.81 (0.73, 0.90). In SpA, the subset of patients with ankylosing spondylitis (AS) showed the best survival on treatment. In RA, both ETA and ADA showed a significantly lower probability of withdrawal when compared to INF [adjHR (95%CI) 0.46 (0.38, 0.56) and 0.68 (0.57, 0.81), respectively]. Similar results were found in SpA. CONCLUSIONS: Drug survival for SpA is longer than that in RA mainly due to the AS subgroup. In both RA and SpA, ETA and ADA showed a better retention on treatment when compared to INF.
2013
31
6
857
863
Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the Monitor Net database / Scirè, Ca; Caporali, R; Sarzi Puttini, P; Frediani, B; Di Franco, M; Tincani, A; Sinigaglia, L; Sfriso, P; Tirri, R; Bellis, E; Delsante, G; Porru, G; Salaffi, F; Giuggioli, D; Rossini, M; Todoerti, M; Bazzichi, L; Govoni, M; Gerli, R; Raschetti, R; Minisola, G; Montecucco, C; Todesco, S; Todesco, S; Raschetti, R; Naldi, L; Galeazzi, M; Sarzi Puttini, P; Fantini, F; Mathieu, A; Valesini, G; Ferri, Clodoveo; Bambara, Lm; Grassi, W; Trotta, F; Gerli, R; Adami, S; Lapadula, G; Pellerito, R; De Vita, S; Minisola, G; Foti, R; Paolazzi, G; Bagnato, G; Cutolo, M; Rocchetta, Pa; Ferraccioli, G; Canesi, Ba; Matucci Cerinic, M; Vittorio, M; Canzoni, M.. - In: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. - ISSN 0392-856X. - STAMPA. - 31:6(2013), pp. 857-863.
Scirè, Ca; Caporali, R; Sarzi Puttini, P; Frediani, B; Di Franco, M; Tincani, A; Sinigaglia, L; Sfriso, P; Tirri, R; Bellis, E; Delsante, G; Porru, G;...espandi
File in questo prodotto:
File Dimensione Formato  
Sciré.pdf

Solo gestori archivio

Descrizione: articolo finale
Tipologia: Versione pubblicata dall'editore
Dimensione 411.64 kB
Formato Adobe PDF
411.64 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1004544
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 47
  • ???jsp.display-item.citation.isi??? 49
social impact